Share on StockTwits
 

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) Director Nathaniel E. David sold 5,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $45.31, for a total transaction of $226,550.00. Following the sale, the director now directly owns 502,384 shares of the company’s stock, valued at approximately $22,763,019. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 1.13% during mid-day trading on Wednesday, hitting $45.035. 213,454 shares of the company’s stock traded hands. KYTHERA Biopharmaceuticals has a one year low of $14.07 and a one year high of $47.85. The stock’s 50-day moving average is $40.72 and its 200-day moving average is $37.46. The company’s market cap is $963.7 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last posted its quarterly earnings results on Thursday, November 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.10. Analysts expect that KYTHERA Biopharmaceuticals will post $-2.74 EPS for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.